Journal of Oncology / 2020 / Article / Tab 9

Research Article

Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece

Table 9

Overall survival and overall progression-free survival according to second-line chemotherapy regimen in the overall population and the group of patients diagnosed during study enrolment.

Median95% CI value

OS (months)
Sequence 120.08.7–31.40.523
Sequence 220.210.0–30.5
Sequence 313.110.8–15.3
Sequence 413.67.6–19.7

PFS (months)
Sequence 118.16.3–29.90.128
Sequence 220.415.2–25.7
Sequence 311.99.0–14.8
Sequence 410.37.1–13.5

Sequence 1 (N = 22): nab-paclitaxel/gemcitabine as first-line followed by FOLFIRINOX/XELOXIRI as second-line treatment. Sequence 2 (N = 19): nab-paclitaxel/gemcitabine as first-line followed by FOLFOX/CAPOX as second-line treatment. Sequence 3 (N = 14): nab-paclitaxel/gemcitabine as first-line followed by other regimens as second-line treatment. Sequence 4 (N = 14): FOLFIRINOX/CAPOXIRI as first-line followed by nab-paclitaxel/gemcitabine as second-line treatment; 95% CI, 95% confidence intervals; OS, overall survival; PFS, progression-free survival.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.